UNASSIGNED: Genotyping of CYP3A5*3, CYP3A4*18 and CYP2B6*6 was performed in 153 patients (102 IM non-responders and 51 IM responders) with CML by the PCR-restriction fragment length polymorphism (RFLP) assays. The odds ratios (ORs) with 95 per cent confidence intervals (CIs) were applied to assess the association between allelic variants and IM therapy outcome. The results were validated by sequencing.
UNASSIGNED: The frequency of the CYP3A4*18 allele was considerably lower in the responder\'s group (97.1 vs. 100%; P=0.036). For CYP3A5*3, the allelic frequency was slightly higher among the IM responders (100 vs. 99.02%) with no significant difference. Although patients heterozygous (TC) for CYP2B6*6 demonstrated a higher risk of acquiring resistance (OR 1.04; 95% CI: 0.492-2.218), differences were not significant (P=0.909). In addition, the homozygous genotype (TT) demonstrated a lower risk of unresponsiveness (OR 0.72; 95% CI: 0.283-1.836), but associations were not significant (P=0.491).
UNASSIGNED: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.
■通过PCR限制性片段长度多态性(RFLP)测定,对153例CML患者(102例IM无应答者和51例IM应答者)进行了CYP3A5*3,CYP3A4*18和CYP2B6*6的基因分型。应用比值比(ORs)和95%置信区间(CIs)来评估等位基因变异与IM治疗结果之间的关联。通过测序验证结果。
■在应答者组中,CYP3A4*18等位基因的频率大大降低(97.1与100%;P=0.036)。对于CYP3A5*3,IM应答者的等位基因频率略高(100vs.99.02%)无显著差异。尽管CYP2B6*6的杂合(TC)患者表现出更高的获得抵抗的风险(OR1.04;95%CI:0.492-2.218),差异无统计学意义(P=0.909)。此外,纯合基因型(TT)表现出较低的无反应风险(OR0.72;95%CI:0.283-1.836),但相关性不显著(P=0.491)。
■我们的结果表明,CYP3A4*18与阿塞拜疆CML患者的IM治疗反应显着相关,而相当常见的CYP3A5*3被鉴定为没有这种关联。